Pomerantz Law Firm Alerts Regeneron Investors on Class Action Lawsuit Status

Pomerantz LLP, a recognized leader in corporate class action litigation, recently announced the initiation of a class action lawsuit against Regeneron Pharmaceuticals, Inc. This legal action raises serious questions about potential securities fraud or misconduct within the company and urges investors who have suffered losses to take action.

Background of the Case

Following the announcement on January 28, 2025, shareholders are encouraged to reach out regarding their investment losses in Regeneron, particularly those who purchased securities during the specified class period. The firm is looking for investors who might wish to take on the role of Lead Plaintiff. Interested individuals have until March 10, 2025, to make their claims known.

The issues at hand trace back to regulatory complaints filed by the U.S. Department of Justice (DOJ), claiming Regeneron failed to disclose significant discounts granted to drug distributors related to credit card fees. This failure allegedly resulted in inflated Average Sales Prices (ASP) for essential treatments, notably Eylea and Eylea HD. Such inaccuracies in financial reporting not only obfuscated the true financial health of the company but also allowed Regeneron to secure an unfair competitive edge over other treatments in the market.

Financial Impact

In light of these developments, Regeneron’s stock experienced a notable decline. Within days of the DOJ’s announcement on April 10, 2024, the stock price plummeted by $31.50, reflecting growing investor concern. Moreover, during the third quarter earnings report released on October 31, 2024, the company reported disappointing sales figures compared to expectations. A mere 3% increase in net sales for Eylea and a significant miss on estimates for Eylea HD resulted in a $84.59 drop in share price.

These developments have triggered alarm among investors, highlighting the importance of transparency and adherence to securities laws. The Pomerantz firm, which has been active in advocating for the rights of shareholders and victims of corporate misconduct for over 85 years, will utilize its expertise to ensure that investors are informed and supported throughout this process.

Call to Action

Affected shareholders are encouraged to act swiftly. If you purchased Regeneron stock within the defined class period, you may be eligible to join the class action by contacting Danielle Peyton at Pomerantz LLP. Ensuring your voice is heard in this significant case could potentially help in recovering losses sustained during the fraudulent actions.

As the situation evolves, it is crucial for investors to stay informed and connected with legal counsel specializing in securities law. Should you be eligible, participating in this class action could be a vital step in seeking justice and recompense for any financial damages incurred as a result of the alleged fraud.

For detailed information on how to join the class action or to access the lawsuit, you can visit Pomerantz LLP's official site or reach out directly for personalized guidance.